The journal of clinical outcome assessment operations
Data Quality & Technology
How FDA's May 2026 CGM technical specifications link SDTM LB epochs, ADCGM phantom rows and ADCGMEN completeness variables, and what the SAP must lock first.
· · 24 min read
Latest
Evidence before assertionWhen competing events occur, choosing between cumulative incidence and cause-specific hazard depends on the probability question and ICH E9(R1) estimand strategy.
How clinical trial teams structure imaging charters to handle reader disagreement, unreadable series, and missing scans before database lock.
How clinical trial teams choose wearable non-wear rules, define valid days, and distinguish missing observations from intercurrent events.
Which endpoint data must be reconciled and evidenced before a clinical database lock, who signs each row, and how unlock and unblinding stay controlled.
Decide which PRO questionnaires a clinical trial needs by mapping objectives, checking combined burden, and justifying timing in a hypothetical worked example.
How to write ClinicalTrials.gov outcome measures from the protocol endpoint, which 42 CFR 11.64 update clock applies after an amendment, and what results QC checks.
What to record when a trial visit falls outside its protocol window, how to classify the deviation, and when the SAP analysis window still counts the endpoint.
Why daily diary averages and 7-day recall scores for the same PRO items diverge, what FDA guidance says about changing a recall period, and what to lock before the eCOA build.
How trial teams timestamp a withdrawal boundary, keep endpoint data already collected in an FDA-regulated database, and stop only the collection the participant has refused.
How data management teams query an endpoint discrepancy without supplying the answer, and what to do when the site confirms the original value.
How clinical trial teams should specify caregiver eligibility, unique credentials, audit trails, and transition sensitivity analyses when diary respondents change.
A pre-build confirmation guide for clinical trial teams: verifying electronic rights, scoring materials, validated translations, and protocol scope before an eCOA build starts.
How clinical trial teams handle offline eCOA entries: resolving wrong device clocks, duplicate records from replacement devices, and preserving audit trails under FDA, EMA, and ICH rules.
How clinical trial teams write a proportionate remote eConsent identity ladder, file the identity note, and handle a missing-document fallback under 21 CFR 11.100, FDA and MHRA/HRA guidance, and the 2025 decentralised-elements recommendation.
How clinical trial teams structure an endpoint adjudication charter and case-packet completeness rules before the first reported event under FDA and ICH E6(R3) guidance.
How clinical trial teams write executable censoring rules for time-to-event endpoints, aligning situation tables with ICH E9(R1) estimands and ADaM datasets.
Resolve eCOA and EDC participant, visit, and timestamp conflicts using prespecified cross-reference keys, visit-window rules, and originator change controls under ICH E6(R3) and EMA guidelines.
How clinical trial teams document patient input that alters trial endpoints—creating an attributable record chain across protocol, registry, and TMF.
How trial teams file endpoint decisions, SAP revisions, eCOA validation, and committee outputs across TMF Reference Model zones for inspection readiness under ICH E6(R3) and EU CTR.
A structured guide for clinical operations, biostatisticians, and outcome leads to convert protocol endpoint risks into centralized monitoring signals with thresholds and actions under ICH E6(R3) and FDA guidance.
How clinical trial teams derive site feasibility questions from protocol endpoints to verify assessment capabilities, score red flags, and inform risk-based monitoring.
How clinical trial teams bind a newly approved eConsent version to already-enrolled participants without treating an upload as reconsent or overwriting original records.
How clinical trial teams bind the current IRB-approved version, an attributable signature, and the participant copy in REDCap before opening enrollment.
How clinical trial teams write executable endpoint definitions in ICH M11 Section 3, integrating SPIRIT-Outcomes elements and aligning Sections 1.3, 7, 8, and 10.
Operationalize COA translation and cultural adaptation in multinational trials, from respondent debriefing to the statistical evidence required to pool endpoint data.
After a named COA is chosen, which reliability, construct-validity, and ability-to-detect-change results still support using that score as a trial endpoint.
How clinical trial teams construct endpoints from fit-for-purpose COAs and prespecify meaningful-change interpretation plans under draft PFDD Guidance 4.
How clinical development teams can evaluate FDA's surrogate endpoint table across indication, mechanism, and approval pathway without conflating listing with formal qualification.
A methodological guide for clinical development and biostatistics teams on FDA, EMRN V02, and ICH E6(R3) Annex 2 rules for collecting trial endpoints away from traditional sites.
A methodological guide to identifying critical-to-quality endpoint factors under ICH E8(R1) and locking definitions, estimands, and feasibility before protocol freeze.
A methodological guide to FDA PFDD Guidance 2 for trial teams to elicit patient-reported disease and treatment burdens before assuming an existing questionnaire defines the concept of interest.
A clinical trial guide for reconciling protocol and lab-manual identity when offered substitute collection kits, separating transport compliance from endpoint assay comparability.
A structured clinical trial guide for documenting therapy identity, supply responsibility, and actual exposure when routine-care or background regimens encounter insurance coverage delays before biostatisticians classify an intercurrent event.
A methodological decision framework for clinical trialists to select among PRO, ClinRO, ObsRO, and PerfO measures based on the concept of interest and context of use before naming an instrument.
A structured guide for trial endpoint leads, laboratories, and biostatisticians on evaluating endpoint observations after an analyzer service event, separating equipment release from data review and SAP handling under 42 CFR 493, ICH E6(R3), and ICH E9(R1).
A methodological guide for biostatistics and clinical development teams on what endpoint definitions, estimand-aligned estimators, and sensitivity analyses the SAP must lock before unblinding.
A methodological framework for clinical operations, biostatistics, and outcome-assessment teams to qualify, train, and monitor ClinRO raters—preventing endpoint drift without relying on start-up certification alone.
A practical release framework for endpoint and data management leads: separating eCOA measurement alterations from schedule and configuration changes under 21 CFR 312.30, 21 CFR 56.108, final PFDD Guidance 3, and EMA Annex 2.10.
A methodological guide for clinical development and biostatistics teams to evaluate measurement comparability across paper, tablet, smartphone, and web modes under the 2023 ISPOR Task Force rule and October 2025 FDA PFDD Guidance 3.
A practical framework for clinical development and quality teams to validate computerized systems capturing trial endpoints—distinguishing platform qualification from protocol configuration under FDA 2024 and EMA 2023 guidelines.
A practical framework for evaluating clinical outcome assessment fitness for purpose under FDA's final PFDD Guidance 3, spanning instrument selection, modification, and evidentiary rationales.
An evidence-based guide to validating digital health technologies (DHTs) for clinical trial endpoints under FDA's December 2023 guidance, covering verification, validation, and missing data.
A methodological guide for clinical development and biostatistics teams to construct ICH E9(R1) estimands, specify intercurrent event strategies, and avoid common missing-data pitfalls.
A methodological guide for biostatisticians and clinical trialists to separate intercurrent events from true missing data and pre-specify same-estimand sensitivity analyses.
A rigorous analysis of multiplicity management in clinical trials, comparing FDA's 2022 final guidance and EMA's 2002 Points to consider across co-primaries, hierarchies, and gatekeeping.
A structured guide for clinical operations, biostatistics, and data management teams to operationalize 21 CFR Part 11 compliance, audit trails, and UAT evidence for eCOA systems.
An evidence-based comparative evaluation of Bring Your Own Device (BYOD), sponsor-provisioned, and hybrid eCOA deployment models across data integrity, psychometrics, and operational costs.
A step-by-step implementation checklist for clinical development and biostatistics teams to align trial endpoints, computerized systems, and data governance with finalized ICH E6(R3) standards.
